Lutetium-177 Rosopatamab Tetraxetan for Metastatic Prostate Cancer

Protocol primary endpoint is rPFS, not OS. OS is typically a secondary endpoint and harder to hit due to crossover, post-progression therapies, and statistical power. Primary completion not until Dec 2027, so OS readout likely later. PSMA-targeted radioligand class has shown OS benefit (Pluvicto/VISION), supporting some signal, but rosopatamab is antibody-based with different PK/toxicity profile and less validation. OS positivity probability modest.

PSMA-selected mCRPC and Phase 3 add-on design give plausible efficacy, but OS is harder than rPFS. The protocol primary endpoint is rPFS, not OS, and active background therapy plus long follow-up create survival-signal and disclosure risk.

Phase 3, recruiting; protocol primary rPFS (337 days, PCWG3/RECIST), OS listed as primary/market endpoint but likely secondary. PSMA-RLT class precedent positive for rPFS/OS but OS maturity at 2027 completion uncertain; powering and follow-up duration not specified.

ProstACT Global's primary endpoint is rPFS; OS is a key secondary. Showing a significant OS benefit in mCRPC is now exceptionally difficult due to control-arm crossover to commercially available therapies like Pluvicto (Lu-PSMA-617), which heavily dilutes the OS signal (as seen in Novartis's PSMAfore trial). Furthermore, OS is typically immature at the rPFS readout.

Phase 3 of Lu-177 rosopatamab in mCRPC. OS is a secondary endpoint (primary is rPFS). Radiopharmaceuticals have shown OS benefit in this setting (e.g., VISION), but many Phase 3 trials fail on OS. Without prior phase 2 data, base rate for OS success in mCRPC is ~35-40%. Moderate confidence due to class effect and lack of drug-specific data.

Protocol endpoint is rPFS, not OS. OS is substantially harder to demonstrate in mCRPC due to crossover and subsequent therapies. Even if rPFS is positive (~50% chance given Lu-177 PSMA class precedent from VISION), OS conversion rate is ~55-60%. Different molecule (antibody vs small-molecule PSMA-617) adds uncertainty. Trial still recruiting; OS data will lag rPFS significantly. Intrinsic OS+ probability ~28%.

Telix's TLX591 has strong Phase 2 data in mCRPC. Adding Lu-177 to standard of care (enzalutamide/abiraterone/docetaxel) targets PSMA+ patients, a validated mechanism (VISION trial). Phase 3 design is robust. Despite early stage, mechanistic plausibility and prior efficacy signal high success probability for OS benefit.

Phase 3 trial is still recruiting, so no efficacy data yet. The intervention adds lutetium‑177 rosopatamab to standard agents in PSMA‑positive mCRPC, a class with demonstrated OS benefit, but the novel agent and combination increase risk. Primary endpoint is OS, a hard endpoint, but early‑stage and operational uncertainties lower confidence, suggesting about a 35% intrinsic chance of a positive OS result.

Phase 3 radioligand therapy in mCRPC. Primary endpoint mismatch: trial uses rPFS (337 days) but market asks OS. OS benefit historically harder to achieve and requires longer follow-up; 553 days to primary completion suggests immature OS data. PSMA-targeted therapies show rPFS benefit but OS signals are mixed (VISION positive, others borderline). Added to existing hormonal/chemo backbone may limit incremental OS gain. Disclosure risk: sponsor may report rPFS first, leaving OS underpowered or negative at interim.

Phase 3 PSMA-targeted radioligand for mCRPC built on plausible mechanism validated by Pluvicto. However, market endpoint is OS while protocol primary is rPFS (337 days) - this mismatch is key risk since rPFS gains may not translate to OS due to subsequent treatments and crossover. Novel antibody agent (rosopatamab) vs established small molecule (vipivotide). Trial still recruiting (553 days out), adding to standard SOC including earlier lines than approved Pluvicto. Endpoint translation uncertainty and novel agent profile support sub-50% OS success odds despite solid biological rationale.